异基因造血干细胞移植可能改善晚期结外NK/T细胞淋巴瘤生存:单中心回顾性研究
该单中心回顾性研究回顾了2019年1月至2024年7月间34例接受异基因造血干细胞移植的复发/难治性结外NK/T细胞淋巴瘤患者的治疗过程。结果显示移植前达到完全或部分缓解者预后更佳,而移植前慢性活动性EBV感染史及移植后EBV再激活与更差生存相关。伴HLH相关基因变异(最常见LYST)者发生HLH后非复发死亡率显著更高,TP53变异与移植后复发相关。
要点
- 移植前达到完全或部分缓解的R/R ENKTCL患者接受allo-HSCT后预后更佳。
- 移植前慢性活动性EBV感染史及移植后EBV再激活与 inferior 生存相关。
- LYST等HLH相关基因变异常见,发生HLH者非复发死亡率显著更高。
核心结论
- allo-HSCT可能改善部分高危晚期R/R ENKTCL患者的生存,但为单中心回顾性假设生成性发现,需多中心更大样本及更长随访验证。
研究设计与样本
- 单中心回顾性研究,纳入2019年1月至2024年7月在该中心接受allo-HSCT的34例R/R ENKTCL患者。
主要发现
- 移植前使用PD-1抑制剂、治疗线数及血浆EBV是否阴性对总生存和无进展生存无显著影响。
- 移植前达到完全缓解或部分缓解的患者预后更佳。
- 移植前有慢性活动性EBV感染史及移植后EBV再激活与更差生存相关。
- 晚期ENKTCL患者常携带HLH相关基因变异,LYST变异最常见,发生HLH者非复发死亡率显著更高。
- TP53基因变异与allo-HSCT后复发相关。
临床怎么用
- 对高危晚期R/R ENKTCL患者,移植前应尽可能达到完全或部分缓解以改善allo-HSCT预后。
- 移植前后需关注EBV状态,移植前慢性活动性EBV感染史及移植后EBV再激活提示预后不良。
- 可关注HLH相关基因(尤其LYST)及TP53变异,发生HLH者非复发死亡风险更高。
局限性
- 单中心回顾性研究,样本量34例,结论为假设生成性,需更大规模多中心及更长随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Extranodal natural killer (NK)/T-cell lymphoma (ENKTCL) is a rare and aggressive lymphoid malignancy highly associated with Epstein-Barr virus (EBV) infection. Patients with stage III or higher disease often have a poor prognosis. This study retrospectively reviewed the treatment courses of 34 patients with relapsed/refractory (R/R) ENKTCL who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at our center between January 2019 and July 2024. The results showed that in this study, the use of programmed cell death protein 1 inhibitors before transplantation, the number of treatment lines, and whether the plasma EBV was negative or not had no significant impact on overall survival and progression-free survival. Patients achieving complete response or partial response before allo-HSCT exhibited a more favorable prognosis. Conversely, a history of chronic active EBV infection before transplantation and EBV reactivation after transplantation were associated with inferior survival, suggesting poor prognostic outcomes. Genetic susceptibility analysis revealed that patients with advanced ENKTCL frequently harbored hemophagocytic lymphohistiocytosis (HLH)-associated gene variants. LYST gene variants were the most commonly identified HLH-related alterations, and patients developing HLH experienced significantly higher nonrelapse mortality. Furthermore, TP53 gene variants were associated with post-allo-HSCT relapse. In conclusion, allo-HSCT may improve survival in selected patients with high-risk, advanced-stage R/R ENKTCL. These single-center, retrospective findings are hypothesis-generating and require validation in larger, multicenter studies with longer follow-up.
引用
- Li Z, Yang K, Wang X, et al. Allogeneic HSCT may improve survival in advanced extranodal NK/T-cell lymphoma: a single-center retrospective study. Blood Adv. 2026. PMID: 42431626. doi:10.1182/bloodadvances.2026020407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。